Andrew Schorr recorded this interview with the president of The American Society of Hematology (ASH) at the start of the conference. CLL is clearly identified as the blood cancer potentially at the treatment cross roads.
“Dr. Janis Abkowitz, hematology-oncology specialist from the Seattle Cancer Care Alliance, details the revolutionary research advances that are opening up a new field of oral medications for blood cancer treatment.”
Here is a more detailed explanation outlining the changing landscape of CLL treatment, recorded during the conference..
“Dr. John Pagel, from the Seattle Cancer Care Alliance, details important advances that signal a changing treatment landscape in CLL.”